Delayed emesis following administration of carboplatin-based chemotherapy despite
prophylaxis with standard antiemetic prophylaxis (5-HT3 and corticosteroid) remains a
clinically significant and distressing problem for patients with cancer. The incidence of
delayed emesis appears to be higher in women compared to men.
All patients will be given the Functional Living Index- Emesis (FLIE), a standardized
questionnaire. This is a self-administered questionnaire to assess the impact of nausea and
vomiting on the patient's functional living, including physical activities, social and
emotional function, and ability to enjoy food and drink. Patients will complete the
questionnaire during the 5 days following carboplatin administration (at 24 hours, 48 hours,
72 hours and 96 hours) during their first and third cycles of chemotherapy. The
questionnaire should take approximately 10 minutes or less to complete.
Patients will also be interviewed by a trained CRA or research nurse over the telephone
24-48 hours following carboplatin administration in order to assess the severity of the
delayed nausea and vomiting.
- Patients must have newly diagnosed, histologically or cytologically proven cancer,
and be scheduled to receive chemotherapy with carboplatin at AUC 5 or above.
- Patients should receive standard antiemetic prophylaxis prior to carboplatin
administration, defined as 5-HT3 antagonist and dexamethasone. We will include only
patients whose standard care includes treatment with a carboplatin-containing regimen
and who are not being treated with aprepitant (Emend®).
- Age >= 18.
- After being informed of the treatment involved, patients must give written consent.
- Entry to this study is open to both men and women and to all racial and ethnic
- No prior cytotoxic chemotherapy within the last 5 years.
- Should not be pregnant.